Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: A randomized controlled trial

JAMA

Volumn 283, Issue 15, 2000, Pages 1995-2002

  Thompson, B Taylor ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; INTERLEUKIN 6; KETOCONAZOLE; THROMBOXANE A2; THROMBOXANE B2;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ARTIFICIAL VENTILATION; BREATHING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; HUMAN; LUNG FUNCTION; LUNG INJURY; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 0343618525     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.15.1995     Document Type: Article

References (31)

1. Kollef MH, Schuster DP. The acute respiratory distress syndrome. N Engl J Med. 1995;332:27-37.
2. Milberg JA, Davis DR, Steinberg KP, Hudson LD. Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993. JAMA. 1995; 273:306-309.
3. Hudson LD, Milberg JA, Anardi D, Maunder RJ. Clinical risks for development of the acute respiratory distress syndrome. Am J Respir Crit Care Med. 1995;151(2 pt 1):293-301.
4. Bernard GR, Artigas A, Brigham KL, et al, and The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994; 149(3 pt 1):818-824.
5. Zilberberg MD, Epstein SK. Acute lung injury in the medical ICU. Am J Respir Crit Care Med. 1998; 157(4 pt 1):1159-1164.
6. Rinaldo JE, Rogers RM. Adult respiratory-distress syndrome: changing concepts of lung injury and repair. N Engl J Med. 1982;306:900-909.
7. Repine JE, Beehler CJ. Neutrophils and adult respiratory distress syndrome: two interlocking perspectives in 1991. Am Rev Respir Dis. 1991;144:251-252.
8. 2 mediates lung vasoconstriction but not permeability after endotoxin. J Clin Invest. 1983; 72:911-918.
9. Tomashefski JF Jr. Pulmonary pathology of the adult respiratory distress syndrome. Clin Chest Med. 1990; 11:593-619.
10. Lyberg T, Nakstad B, Hetland Ø, Boye NP. Procoagulant (thromboplastin) activity in human bronchoalveolar lavage fluids is derived from alveolar macrophages. Eur Respir J. 1990;3:61-67.
11. Williams JG, Maier RV. Ketoconazole inhibits alveolar macrophage production of inflammatory mediators involved in acute lung injury (adult respiratory distress syndrome). Surgery. 1992;112:270-277.
12. Lelcuk S, Huval WV, Valeri CR, Shepro D, Hechtman HB. Inhibition of ischemia-induced thromboxane synthesis in man. J Trauma. 1984;24:393-396.
13. Slotman GJ, Burchard KW, D'Arezzo A, Gann DS. Ketoconazole prevents acute respiratory failure in critically ill surgical patients. J Trauma. 1988;28:648-654.
14. Yu M, Tomasa G. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med. 1993;21: 1635-1642.
15. Sinuff T, Cook DJ, Peterson JC, Fuller HD. Development, implementation, and evaluation of a ketoconazole practice guideline for ARDS prophylaxis. J Crit Care. 1999;14:1-6.
16. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome [New England Journal of Medicine Web site]. Available at: http://www.nejm.org. Accessed March 10, 2000.
17. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60: 646-649.
18. Sugar EF, Sugar AM, Kreger BE. Effect of various common beverages on the dissolution of ketoconazole tablets. AIDS. 1992;6:1221-1222.
19. Bodet CA III, Jorgensen JH, Drutz DJ. Simplified bioassay method for measurement of flucytosine or ketoconazole. J Clin Microbiol. 1985;22:157-160.
20. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system: risk prediction of hospital mortality for critically ill hospitalized adults. Chest. 1991;100:1619-1636.
21. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549-556.
22. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome [published correction appears in Am Rev Respir Dis. 1989;139:1065] Am Rev Respir Dis. 1988; 138:720-723.
23. Van Tyle JH. Ketoconazole: mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use. Pharmacotherapy. 1984;4:343-373.
24. Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ. Effects of ranitidine and sucralfate on ketoconazole bioavailability. Antimicrob Agents Chemother. 1991;35:1765-1771.
25. Chin TW, Loeb M, Fong IW. Effects of Coca-Cola on the oral absorption of ketoconazole in the presence of achlorhydria [abstract]. Antimicrob Agents Chemother. 1993;A143S:382.
26. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet. 1988;14:13-34.
27. 2 metabolites in humans. Thromb Res. 1987;47:647-656.
28. Donnelly TJ, Meade P, Jagels M, et al. Cytokine, complement, and endotoxin profiles associated with the development of the adult respiratory distress syndrome after severe injury. Crit Care Med. 1994;22: 768-776.
29. Bonten MJ, Froon AH, Gaillard CA, et al. The systemic inflammatory response in the development of ventilator-associated pneumonia. Am J Respir Crit Care Med. 1997;156(4 pt 1):1105-1113.
30. Weksler BB, Pett SB, Alonso D, et al. Differential inhibition by aspirin of vascular and platelet prosta-glandin synthesis in atherosclerotic patients. N Engl J Med. 1983;308:800-805.
31. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med. 1996;334: 1697-1702.